サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1536675

糖尿病性神経障害治療市場：疾患タイプ別、薬剤クラス別、流通チャネル別、国別、地域別- 産業分析、市場規模、市場シェア、2024年～2032年予測

Diabetic Neuropathy Treatment Market, By Disease Type, By Drug Class, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日: | 発行: AnalystView Market Insights | ページ情報: 英文 288 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.72円
糖尿病性神経障害治療市場：疾患タイプ別、薬剤クラス別、流通チャネル別、国別、地域別- 産業分析、市場規模、市場シェア、2024年～2032年予測
出版日: 2024年08月04日
発行: AnalystView Market Insights
ページ情報: 英文 288 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

糖尿病性神経障害治療市場規模は2023年に43億9,032万米ドルとなり、2024年から2032年にかけてCAGR 8.10%で拡大

糖尿病性神経障害治療市場-市場力学

糖尿病治療における診断技術の向上と革新的治療が市場需要を促進すると予測

糖尿病、特に2型糖尿病の世界の罹患率の増加は、市場成長の主要な促進要因です。糖尿病患者の増加に伴い、糖尿病性神経障害などの合併症に対する効果的な治療に対する需要も増加しています。診断技術の進歩と認知度の向上は、糖尿病性神経障害の早期かつ正確な診断につながります。早期診断がより良い管理と治療成績につながることが多く、治療に対する需要が増加しています。新興市場におけるヘルスケア支出の増加と医療インフラの改善は、糖尿病性神経障害治療市場の成長に寄与しています。

新規医薬品、生物製剤、医療機器など、新しい治療法や治療法の研究への投資の増加が市場成長に寄与しています。ドラッグデリバリーシステムや治療アプローチの革新が治療の選択肢を広げます。糖尿病の研究・治療に対する政府の取り組みや資金援助、糖尿病性神経障害治療に対する有利な償還政策が市場の成長を支えています。特定の神経障害性疼痛経路を標的とするものや、より優れた有効性と安全性プロファイルを提供するものなど、新薬や治療法の市場導入が市場成長を促進します。

糖尿病性神経障害治療市場-主要インサイト

弊社リサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）に約8.10%のCAGRで毎年成長すると予測されています。

疾患タイプ別セグメントでは、末梢神経障害が糖尿病性神経障害の最も一般的な形態の1つであるため、2023年に最大の市場シェアを示すと予測されました。

薬剤クラス別では、非ステロイド性抗炎症薬（NSAIDs）が2023年の主要薬剤クラスでした。

流通チャネル別では、病院薬局での投薬が多いことから、2023年の流通チャネルは病院薬局がトップでした。

地域別では、北米は糖尿病治療のためのヘルスケアインフラが発達していることから、2023年の売上高をリードしています。

糖尿病性神経障害治療市場-セグメンテーション分析：

世界の糖尿病性神経障害治療市場は、疾患タイプ、薬剤クラス別、流通チャネル、地域別に区分されます。

疾患タイプ別に見ると、末梢神経障害、自律神経障害、近位神経障害、局所神経障害の4つに分類されます。末梢神経障害分野が市場を独占しています。高齢者の糖尿病有病率の高さがこのセグメントの需要を押し上げています。

市場は薬剤クラス別にカプサイシン、オピオイド、非ステロイド性抗炎症薬（NSAIDs）、その他の4つに分類されます。非ステロイド性抗炎症薬（NSAIDs）セグメントは市場で最大のシェアを占めると予測されています。オピオイド分野は予測期間中最も速い速度で成長すると予測されます。オピオイドは強力な鎮痛薬であり、より効果的な鎮痛をもたらすことができます。

市場は流通チャネルによって、病院薬局、小売薬局、その他の3つに分類されます。病院薬局セグメントが市場を独占しており、予測期間中も高い優位性を維持すると予想されます。病院薬局は、薬剤を管理するための統合システムを有しているため、処理が容易であり、そのため導入が進んでいます。

糖尿病性神経障害治療市場-地理的洞察

地理的には、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの地域に広がっています。米国を中心とする北米は、糖尿病の有病率が高く、ヘルスケアインフラが発達しているため、世界の糖尿病性神経障害治療市場で大きなシェアを占めています。中国やインドなどのアジア太平洋地域は、糖尿病罹患率の上昇とヘルスケアインフラの改善により、糖尿病性神経障害治療市場が急成長しています。

糖尿病性神経障害治療市場-競合情勢：

糖尿病性神経障害治療市場は、多くの企業が糖尿病治療ソリューションの開発・提供に携わっており、競争は中程度です。市場参入企業は、新しい製剤や標的療法など、糖尿病性神経障害に関連する特定の疼痛経路をターゲットにした新薬の開発に取り組んでいます。糖尿病有病率の上昇とヘルスケア・インフラの拡大により、企業はアジア太平洋やラテンアメリカなどの新興市場への注力を強めています。

目次

第1章 糖尿病性神経障害治療市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 糖尿病性神経障害治療の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 糖尿病性神経障害治療産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 糖尿病性神経障害治療市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 糖尿病性神経障害治療市場情勢

  • 糖尿病性神経障害治療市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 糖尿病性神経障害治療市場- 疾患タイプ別

  • 概要
    • 疾病タイプ別セグメントシェア分析
    • 末梢神経障害
    • 自律神経障害
    • 近位神経障害
    • 局所神経障害

第8章 糖尿病性神経障害治療市場-薬剤クラス別

  • 概要
    • 薬剤クラス別セグメントシェア分析
    • カプサイシン
    • オピオイド
    • 非ステロイド性抗炎症薬（NSAID）
    • その他

第9章 糖尿病性神経障害治療市場- 流通チャネル別

  • 概要
    • 流通チャネル別セグメントシェア分析
    • 病院薬局
    • 小売薬局
    • その他

第10章 糖尿病性神経障害治療市場-地域

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析- 糖尿病性神経障害治療業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Pfizer Inc.
    • Eli Lilly and Company
    • Astellas Pharma Inc.
    • GlaxoSmithKline plc.
    • Boehringer Ingelheim
    • NeuroMetrix Inc.
    • Axovant Gene Therapies Ltd.
    • Eton Pharmaceuticals
    • Alnylam Pharmaceuticals
    • Novartis International AG
    • Sanofi
    • Johnson &Johnson
    • Amgen Inc.
    • AbbVie Inc.
    • Merck &Co.
    • Vertex Pharmaceuticals
    • Others

第12章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Diabetic Neuropathy Treatment Market: Disease Type Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Disease Type
  • TABLE Global Diabetic Neuropathy Treatment Market, by Disease Type 2019-2032 (USD Million)
  • TABLE Diabetic Neuropathy Treatment Market: Drug Class Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Diabetic Neuropathy Treatment Market, by Drug Class 2019-2032 (USD Million)
  • TABLE Diabetic Neuropathy Treatment Market: Distribution Channel Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Diabetic Neuropathy Treatment Market, by Distribution Channel 2019-2032 (USD Million)
  • TABLE Diabetic Neuropathy Treatment Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Diabetic Neuropathy Treatment Market, by Region 2019-2032 (USD Million)
  • TABLE North America Diabetic Neuropathy Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Diabetic Neuropathy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • TABLE North America Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE North America Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Europe Diabetic Neuropathy Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Diabetic Neuropathy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • TABLE Europe Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Europe Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Asia Pacific Diabetic Neuropathy Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Diabetic Neuropathy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • TABLE Asia Pacific Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Asia Pacific Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Latin America Diabetic Neuropathy Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Diabetic Neuropathy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • TABLE Latin America Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Latin America Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Diabetic Neuropathy Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Diabetic Neuropathy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
目次
Product Code: ANV3524

REPORT HIGHLIGHT

Diabetic Neuropathy Treatment Market size was valued at USD 4,390.32 Million in 2023, expanding at a CAGR of 8.10% from 2024 to 2032.

Diabetic neuropathy is a type of nerve damage that can occur in people with diabetes, usually because of prolonged high blood sugar levels. Treatment typically focuses on managing symptoms and preventing further nerve damage.

Diabetic Neuropathy Treatment Market- Market Dynamics

Improved diagnostic techniques in diabetes treatment and innovative therapies are expected to propel market demand

The growing incidence of diabetes, particularly type 2 diabetes, worldwide is a key driver of the market growth. As the number of diabetes patients increases, so does the demand for effective treatments for complications such as diabetic neuropathy. Advances in diagnostic technologies and increased awareness lead to earlier and more accurate diagnosis of diabetic neuropathy. Early diagnosis often leads to better management and treatment outcomes, increasing the demand for therapies. Higher healthcare spending and improved healthcare infrastructure in emerging markets contribute to the growth of the diabetic neuropathy treatment market.

Increasing investment into research & new treatments and therapies, including novel pharmaceuticals, biologics, and medical devices, contributes to market growth. Innovations in drug delivery systems and therapeutic approaches enhance treatment options. Government initiatives and funding for diabetes research and treatment, as well as favorable reimbursement policies for diabetic neuropathy therapies, support market growth. The introduction of new drugs and therapies into the market, including those targeting specific neuropathic pain pathways or providing better efficacy and safety profiles, drives market growth.

Diabetic Neuropathy Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.10% over the forecast period (2024-2032)

Based on Disease Type segmentation, the peripheral neuropathy segment was predicted to show maximum market share in the year 2023, as it is one of the most common forms of diabetic neuropathy.

Based on Drug Class segmentation, the non-steroidal anti-inflammatory drugs (NSAIDs) segment was the leading Drug Class in 2023, due to its affordability in the market.

Based on Distribution Channel segmentation, the hospital pharmacies segment was the leading Distribution Channel in 2023, owing to high medication at hospital pharmacies.

On the basis of region, North America was the leading revenue generator in 2023, owing to the presence of developed healthcare infrastructure for diabetic treatment.

Diabetic Neuropathy Treatment Market- Segmentation Analysis:

The Global Diabetic Neuropathy Treatment Market is segmented on the basis of Disease Type, Drug Class, Distribution Channel, and Region.

The market is divided into four categories based on Disease Type: peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. The peripheral neuropathy segment dominates the market. The high prevalence of diabetes among old adults is boosting segment demand.

The market is divided into four categories based on Drug Class: capsaicin, opioid, Non-Steroidal Anti-inflammatory Drugs (NSAIDs), and others. The Non-Steroidal Anti-inflammatory Drugs (NSAIDs) segment is projected to hold the largest share of the market. The opioid segment is estimated to grow at the fastest rate over the forecast period. Opioids are potent analgesics that can provide more effective pain relief.

The market is divided into three categories based on Distribution channels: hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment dominates the market and is expected to maintain its high dominance during the forecast period. Hospital pharmacies have an integrated system for managing medications, which makes it easier to process and hence have greater adoption.

Diabetic Neuropathy Treatment Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America, predominantly the United States, holds a significant share of the global diabetic neuropathy treatment market due to a high prevalence of diabetes and advanced healthcare infrastructure. The Asia-Pacific region, including countries like China and India, is experiencing rapid growth in the diabetic neuropathy treatment market due to rising diabetes rates and improving healthcare infrastructure.

Diabetic Neuropathy Treatment Market- Competitive Landscape:

The diabetic neuropathy treatment market is moderately competitive, with numerous companies involved in developing and offering diabetic treatment solutions. Market players are working on novel drugs targeting specific pain pathways associated with diabetic neuropathy including new formulations and targeted therapies. Companies are increasingly focusing on emerging markets such as Asia-Pacific and Latin America due to the rising prevalence of diabetes and expanding healthcare infrastructure.

Recent Developments:

In December 2023, Vertex Pharmaceuticals got FDA approval for CRISPR-based gene editing therapy, a strategic move which focuses on the development of non-opioid pain management drugs.

In July 2023, Asprius Lifesciences, an Indian pharmaceutical company, has launched a treatment for Diabetic Neuropathy, a condition causing nerve damage.

In 2022, Axovant Gene Therapies is exploring advanced treatments including gene and cell therapies for neurological conditions.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET KEY PLAYERS

  • Pfizer Inc.
  • Eli Lilly and Company
  • Astellas Pharma Inc.
  • GlaxoSmithKline plc.
  • Boehringer Ingelheim
  • NeuroMetrix Inc.
  • Axovant Gene Therapies Ltd.
  • Eton Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Novartis International AG
  • Sanofi
  • Johnson & Johnson
  • Amgen Inc.
  • AbbVie Inc.
  • Merck & Co.
  • Vertex Pharmaceuticals
  • Others

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019-2032

  • Peripheral neuropathy
  • Autonomic neuropathy
  • Proximal neuropathy
  • Focal neuropathy

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019-2032

  • Capsaicin
  • Opioid
  • Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
  • Others

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019-2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Diabetic Neuropathy Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Diabetic Neuropathy Treatment Market Snippet by Disease Type
    • 2.1.2. Diabetic Neuropathy Treatment Market Snippet by Drug Class
    • 2.1.3. Diabetic Neuropathy Treatment Market Snippet by Distribution Channel
    • 2.1.4. Diabetic Neuropathy Treatment Market Snippet by Country
    • 2.1.5. Diabetic Neuropathy Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Diabetic Neuropathy Treatment Key Market Trends

  • 3.1. Diabetic Neuropathy Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Diabetic Neuropathy Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Diabetic Neuropathy Treatment Market Opportunities
  • 3.4. Diabetic Neuropathy Treatment Market Future Trends

4. Diabetic Neuropathy Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Diabetic Neuropathy Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Diabetic Neuropathy Treatment Market Landscape

  • 6.1. Diabetic Neuropathy Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Diabetic Neuropathy Treatment Market - By Disease Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Disease Type, 2024 & 2032 (%)
    • 7.1.2. Peripheral neuropathy
    • 7.1.3. Autonomic neuropathy
    • 7.1.4. Proximal neuropathy
    • 7.1.5. Focal neuropathy

8. Diabetic Neuropathy Treatment Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
    • 8.1.2. Capsaicin
    • 8.1.3. Opioid
    • 8.1.4. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
    • 8.1.5. Others

9. Diabetic Neuropathy Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Others

10. Diabetic Neuropathy Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Diabetic Neuropathy Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Diabetic Neuropathy Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Diabetic Neuropathy Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Diabetic Neuropathy Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Diabetic Neuropathy Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Diabetic Neuropathy Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
    • 11.2.2. Eli Lilly and Company
    • 11.2.3. Astellas Pharma Inc.
    • 11.2.4. GlaxoSmithKline plc.
    • 11.2.5. Boehringer Ingelheim
    • 11.2.6. NeuroMetrix Inc.
    • 11.2.7. Axovant Gene Therapies Ltd.
    • 11.2.8. Eton Pharmaceuticals
    • 11.2.9. Alnylam Pharmaceuticals
    • 11.2.10. Novartis International AG
    • 11.2.11. Sanofi
    • 11.2.12. Johnson & Johnson
    • 11.2.13. Amgen Inc.
    • 11.2.14. AbbVie Inc.
    • 11.2.15. Merck & Co.
    • 11.2.16. Vertex Pharmaceuticals
    • 11.2.17. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us